Skip to content

Newark, CA, November 19, 2018 – FlemingMartin is pleased to announce that Revance Therapeutics (NASDAQ: RVNC), a pioneering biotechnology company focused on the development and commercialization of botulinum toxin (Botox) products for cosmetic and therapeutic applications, has hired Dom Vitarella to be their new Senior Director of Clinical Development for Dermatology.

Mr. Vitarella brings impressive neurotoxins expertise to Revance from two decades with Bonti, Allergan, and Valeant Pharmaceuticals. In his most recent role, Mr. Vitarella drove Clinical Development at Bonti (a company developing fast-acting, novel neurotoxin products). Bonti’s successful sale to Allergan was announced in September 2018.

Mr. Vitarella holds a Ph.D. and M.S. in Pharmacology and Toxicology from Albany Medical College along with an undergraduate degree from Binghamton University.

Revance LogoRevance Therapeutics (NASDAQ: RVNC) is a pioneering biotechnology company committed to the advancement of remarkable science. The Company is poised to enter, and potentially redefine, the neuromodulator aesthetic and therapeutic product categories. Revance’s proprietary peptide technology, when combined with active drug molecules, may help address current unmet needs in dermatology, neurology, and musculoskeletal disorders.


Fleming Martin Color Logo Large 72 PpiFlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms, and CEOs to build successful execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.